CYTOKINETICS INC

Form 4 January 04, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person * **GAGE L PATRICK**

280 EAST GRAND AVENUE

(First) (Middle)

2. Issuer Name and Ticker or Trading Symbol

CYTOKINETICS INC [CYTK]

3. Date of Earliest Transaction (Month/Day/Year) 01/02/2013

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

5. Relationship of Reporting Person(s) to

(Check all applicable)

Person

below)

Issuer

X_ Director

Officer (give title

SOUTH SAN FRANCISCO, CA 94080

1. Title of 2. Transaction Date 2A. Deemed

(State)

Security (Instr. 3)

(Month/Day/Year) Execution Date, if (Month/Day/Year)

(Zip)

3.

4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

Code V Amount (D) Price

(A)

or

5. Amount of Securities Beneficially Owned Following Reported

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

6. Ownership Form: Direct (I) (Instr. 4)

7. Nature of Indirect (D) or Indirect Beneficial Ownership (Instr. 4)

10% Owner

Other (specify

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Transaction(s) (Instr. 3 and 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

Conversion or Exercise

3. Transaction Date 3A. Deemed (Month/Day/Year)

Execution Date, if any

5. Number of TransactionDerivative Code Securities

6. Date Exercisable and **Expiration Date** (Month/Day/Year)

7. Title and A Underlying S (Instr. 3 and

Edgar Filing: CYTOKINETICS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 0.6702	01/02/2013		A	223,813	02/02/2013(1)	01/02/2023	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 0.91					06/22/2012(3)	05/22/2022	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 0.98					02/03/2012(4)	01/03/2022	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 1.44					06/18/2011(5)	05/18/2021	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 2.16					02/03/2011(6)	01/03/2021	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 2.81					06/20/2010(7)	05/20/2020	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 3.33					12/05/2009(8)	11/05/2019	Common Stock

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

GAGE L PATRICK
280 EAST GRAND AVENUE X
SOUTH SAN FRANCISCO, CA 94080

Signatures

By: Sharon A. Barbari For: L. Patrick Gage 01/04/2013

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

Edgar Filing: CYTOKINETICS INC - Form 4

- (1) This option shall vest and become exercisable as to 223,813 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2014.
- (2) This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of \$60,000.
- (3) This option shall vest and become exercisable as to 25,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 22, 2013.
- (4) This option shall vest and become exercisable as to 102,040 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2013.
- (5) This option shall vest and become exercisable as to 20,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 18, 2012.
- (6) This option shall vest and become exercisable as to 46,296 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2012.
- (7) This option shall vest and become exercisable as to 20,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 20, 2011.
- (8) This option shall vest and become exercisable as to 833 shares on 12/05/09 and the balance of 29,167 divided into equal monthly installments thereafter such that the option shall be 100% vested on 11/05/12.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.